GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sanofi (SNY) shares

Learn how to easily invest in Sanofi shares.

Sanofi is a drug manufacturers-general business based in the US. Sanofi shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi employs 99,412 staff and has a trailing 12-month revenue of around USD$37.5 billion.

How to buy shares in Sanofi

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SNY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Global markets
Your capital is at risk.
Saxo Markets
Global markets
Your capital is at risk.
CFD Service. Your capital is at risk.
BlackBull Markets
CFD Service. Your capital is at risk.
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.

Compare up to 4 providers

How has Coronavirus impacted Sanofi's stock price?

Since the stock market crash in March caused by coronavirus, Sanofi's stock price has had significant negative movement.

Its last market close was $48.85, which is 3.93% down on its pre-crash value of $50.85 and 29.85% up on the lowest point reached during the March crash when the stocks fell as low as $37.62.

If you had bought $1,000 worth of Sanofi stocks at the start of February 2020, those stocks would have been worth $797.24 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,009.73.

Is it a good time to buy Sanofi stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sanofi shares at a glance

Information last updated 2021-10-15.
Latest market close$48.85
52-week range$43.13 - $54.26
50-day moving average $49.22
200-day moving average $51.24
Wall St. target price$64.63
PE ratio 18.2856
Dividend yield $3.2 (6.59%)
Earnings per share (TTM) $2.67

Sanofi stock price (NASDAQ: SNY)

Use our graph to track the performance of SNY stocks over time.

Sanofi price performance over time

Historical closes compared with the close of $48.85 from 2021-10-15

1 week (2021-10-11) 0.35%
1 month (2021-09-17) 0.97%
3 months (2021-07-17) -5.02%
6 months (2021-04-16) -4.78%
1 year (2020-10-16) -2.82%
2 years (2019-10-18) 5.80%
3 years (2018-10-18) 9.90%
5 years (2016-10-18) 29.47%

Is Sanofi under- or over-valued?

Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sanofi's P/E ratio

Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Sanofi shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sanofi's PEG ratio

Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0348. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sanofi's EBITDA

Sanofi's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 billion.

The EBITDA is a measure of a Sanofi's overall financial performance and is widely used to measure a its profitability.

Sanofi financials

Revenue TTM $37.5 billion
Operating margin TTM 21.52%
Gross profit TTM $25.3 billion
Return on assets TTM 4.43%
Return on equity TTM 9.22%
Profit margin 15.47%
Book value $25.24
Market capitalisation $123.1 billion

TTM: trailing 12 months

Shorting Sanofi shares

There are currently 7.1 million Sanofi shares held short by investors – that's known as Sanofi's "short interest". This figure is 26.8% up from 5.6 million last month.

There are a few different ways that this level of interest in shorting Sanofi shares can be evaluated.

Sanofi's "short interest ratio" (SIR)

Sanofi's "short interest ratio" (SIR) is the quantity of Sanofi shares currently shorted divided by the average quantity of Sanofi shares traded daily (recently around 2.4 million). Sanofi's SIR currently stands at 2.9. In other words for every 100,000 Sanofi shares traded daily on the market, roughly 2900 shares are currently held short.

However Sanofi's short interest can also be evaluated against the total number of Sanofi shares, or, against the total number of tradable Sanofi shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sanofi's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sanofi shares in existence, roughly 0 shares are currently held short) or 0.0032% of the tradable shares (for every 100,000 tradable Sanofi shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sanofi.

Sanofi share dividends


Dividend payout ratio: 52.96% of net profits

Recently Sanofi has paid out, on average, around 52.96% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.97% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.97% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $3.2 per share.

Sanofi's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Sanofi's most recent dividend payout was on 25 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 May 2021 (the "ex-dividend date").

Have Sanofi's shares ever split?

Sanofi's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi shares which in turn could have impacted Sanofi's share price.

Sanofi share price volatility

Over the last 12 months, Sanofi's shares have ranged in value from as little as $43.131 up to $54.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.4131. This would suggest that Sanofi's shares are less volatile than average (for this exchange).

Sanofi overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site